For the first time, traditional drug spending has exceeded specialty drug spending, largely due to the demand for GLP-1s, according to a new report from Evernorth Research Institute. Evernorth ...
Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results